Skip to main content
Premium Trial:

Request an Annual Quote

City of Hope to Use DxTerity Diagnostics Platform in Antisense Program

NEW YORK (GenomeWeb News) – DxTerity Diagnostics last night said that the City of Hope research center will use the firm’s Non-Enzymatic Amplification Technology, or NEAT, genomics testing platform in a program to develop antisense therapeutics.
DxTerity’s platform enables gene-controlled ligation of oligonucleotide probes inside of cells, the Rancho Dominguez, Calif.-based firm said. In addition to applying the technology to therapeutics development, the platform enables the development of “simple and affordable nucleic acid-based tests,” said DxTerity.
City of Hope researchers believe the technology could potentially help develop a new class of therapeutics with reduced side effects.
Terms of the agreement were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.